Literature DB >> 27042841

Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.

M Martino1, R M Lemoli2, C Girmenia3, L Castagna4, B Bruno5, F Cavallo5, M Offidani6, I Scortechini6, M Montanari6, G Milone7, L Postacchini8, A Olivieri6.   

Abstract

Multiple myeloma (MM) is the leading indication for autologous stem cell transplantation (ASCT) worldwide. The safety and efficacy of reducing hospital stay for MM patients undergoing ASCT have been widely explored, and different outpatient models have been proposed. However, there is no agreement on the criteria for selecting patients eligible for this strategy as well as the standards for their clinical management. On the basis of this rationale, the Italian Group for Stem Cell Transplantation (GITMO) endorsed a project to develop guidelines for the management of outpatient ASCT in MM, using evidence-based knowledge and consensus-formation techniques. An expert panel convened to discuss the currently available data on the practice of outpatient ASCT management and formulated recommendations according to the supporting evidence. Evidence gaps were filled with consensus-based statements. Three main topics were addressed: (1) the identification of criteria for selecting MM patients eligible for outpatient ASCT management; (2) the definition of standard procedures for performing outpatient ASCT (model, supportive care and monitoring during the aplastic phase); (3) the definition of the standard criteria and procedures for re-hospitalization during the aplastic phase at home. Herein, we report the summary and the results of the discussion and the consensus.

Entities:  

Mesh:

Year:  2016        PMID: 27042841     DOI: 10.1038/bmt.2016.79

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  71 in total

1.  200 mg/m(2) melphalan--the gold standard for multiple myeloma.

Authors:  Sergio Giralt
Journal:  Nat Rev Clin Oncol       Date:  2010-09       Impact factor: 66.675

2.  Best practice recommendations in: (1) Peripheral blood stem cell mobilization and collection and (2) acute and chronic GvHD treatment using extracorporeal photopheresis. A joint effort from SIdEM (Società Italiana di Emaferesi e Manipolazione Cellulare) and GITMO (Gruppo Italiano Trapianto di Midollo Osseo).

Authors:  P Perseghin; M Marchetti; C Messina; A Mazzoni; P Carlier; C Perotti; L Salvaneschi; M Risso; R Fanin; A Olivieri; P Accorsi; F Locatelli; A Bacigalupo; L Pierelli; A Bosi
Journal:  Transfus Apher Sci       Date:  2013-03-16       Impact factor: 1.764

3.  Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years.

Authors:  A Badros; B Barlogie; E Siegel; C Morris; R Desikan; M Zangari; A Fassas; E Anaissie; N Munshi; G Tricot
Journal:  Br J Haematol       Date:  2001-09       Impact factor: 6.998

4.  Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.

Authors:  H W Auner; R Szydlo; J Hoek; H Goldschmidt; A M Stoppa; G J Morgan; P Moreau; M Attal; G Marit; N Russell; M Brune; G Cook; P Sonneveld; S Schönland; L Garderet; N Kröger
Journal:  Bone Marrow Transplant       Date:  2014-11-10       Impact factor: 5.483

5.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Authors:  Michele Cavo; Paola Tacchetti; Francesca Patriarca; Maria Teresa Petrucci; Lucia Pantani; Monica Galli; Francesco Di Raimondo; Claudia Crippa; Elena Zamagni; Antonio Palumbo; Massimo Offidani; Paolo Corradini; Franco Narni; Antonio Spadano; Norbert Pescosta; Giorgio Lambertenghi Deliliers; Antonio Ledda; Claudia Cellini; Tommaso Caravita; Patrizia Tosi; Michele Baccarani
Journal:  Lancet       Date:  2010-12-09       Impact factor: 79.321

6.  Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.

Authors:  Patrizia Tosi; Elena Zamagni; Paola Tacchetti; Michela Ceccolini; Giulia Perrone; Annamaria Brioli; Maria Caterina Pallotti; Lucia Pantani; Alessandro Petrucci; Michele Baccarani; Michele Cavo
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-01       Impact factor: 5.742

7.  Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative.

Authors:  Morie A Gertz; Stephen M Ansell; David Dingli; Angela Dispenzieri; Francis K Buadi; Michelle A Elliott; Dennis A Gastineau; Suzanne R Hayman; William J Hogan; David J Inwards; Patrick B Johnston; Shaji Kumar; Martha Q Lacy; Nelson Leung; Ivana N M Micallef; Luis F Porrata; Barbara A Schafer; Robert C Wolf; Mark R Litzow
Journal:  Mayo Clin Proc       Date:  2008-10       Impact factor: 7.616

8.  The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer.

Authors:  W P Peters; M Ross; J J Vredenburgh; A Hussein; P Rubin; K Dukelow; C Cavanaugh; R Beauvais; S Kasprzak
Journal:  Semin Oncol       Date:  1994-08       Impact factor: 4.929

9.  Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age.

Authors:  Philip L McCarthy; Theresa Hahn; Anna Hassebroek; Christopher Bredeson; James Gajewski; Gregory Hale; Luis Isola; Hillard M Lazarus; Stephanie J Lee; Charles F Lemaistre; Fausto Loberiza; Richard T Maziarz; J Douglas Rizzo; Steven Joffe; Susan Parsons; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2013-05-06       Impact factor: 5.742

10.  Bacteremia in blood or marrow transplantation patients: clinical risk factors for infection and emerging antibiotic resistance.

Authors:  Allison M Bock; Qing Cao; Patricia Ferrieri; Jo-Anne H Young; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-29       Impact factor: 5.742

View more
  7 in total

1.  Safety and cost-effectiveness of outpatient autologous transplantation for multiple myeloma in Asia: single-center perspective from Singapore.

Authors:  M B Abid; D Christopher; M A Abid; M L Poon; L K Tan; L P Koh; W J Chng
Journal:  Bone Marrow Transplant       Date:  2017-05-08       Impact factor: 5.483

2.  Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.

Authors:  Adrian A Carballo-Zarate; L Jeffrey Medeiros; Lianghua Fang; Jatin J Shah; Donna M Weber; Sheeba K Thomas; Elisabet E Manasanch; Suyang Hao; Qi Shen; Robert Z Orlowski; Pei Lin; Xinyan Lu
Journal:  Mod Pathol       Date:  2017-03-10       Impact factor: 7.842

3.  Cellular Therapies for Treatment of Radiation Injury: Report from a NIH/NIAID and IRSN Workshop.

Authors:  Andrea L DiCarlo; Radia Tamarat; Carmen I Rios; Marc Benderitter; Christine W Czarniecki; Theresa C Allio; Francesca Macchiarini; Bert W Maidment; Jean-Rene Jourdain
Journal:  Radiat Res       Date:  2017-06-12       Impact factor: 2.841

4.  Safety and feasibility of outpatient autologous stem cell transplantation in pediatric patients with primary central nervous system tumors.

Authors:  Jane Koo; Stacy Silverman; Brandon Nuechterlein; Amy K Keating; Michael R Verneris; Nicholas K Foreman; Jean M Mulcahy Levy
Journal:  Bone Marrow Transplant       Date:  2019-02-19       Impact factor: 5.483

Review 5.  Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art.

Authors:  Massimo Martino; Annalisa Paviglianiti; Mara Memoli; Giovanni Martinelli; Claudio Cerchione
Journal:  Front Oncol       Date:  2020-11-11       Impact factor: 6.244

6.  The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever.

Authors:  Luis-Gerardo Rodríguez-Lobato; Alexandra Martínez-Roca; Sandra Castaño-Díez; Alicia Palomino-Mosquera; Gonzalo Gutiérrez-García; Alexandra Pedraza; María Suárez-Lledó; Montserrat Rovira; Carmen Martínez; Carlos Fernández de Larrea; María-Teresa Cibeira; Laura Rosiñol; Ester Lozano; Pedro Marín; Joan Cid; Miquel Lozano; Ana Belén Moreno-Castaño; Marta Palomo; Maribel Díaz-Ricart; Cristina Gallego; Adelina Hernando; Susana Segura; Enric Carreras; Álvaro Urbano-Ispizua; Joan Bladé; Francesc Fernández-Avilés
Journal:  PLoS One       Date:  2020-11-04       Impact factor: 3.240

7.  Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission.

Authors:  Kristin Larsen; Horace Spencer; Meera Mohan; Clyde Bailey; Kerri Hill; Mathew Kottarathara; Richa Parikh; Shadiqul Hoque; Amani Erra; Angel A Mitma; Pankaj Mathur; Lakshmi Yarlagadda; Sravani Gundarlapalli; Yetunde Ogunsesan; Munawwar Hussain; Nishanth Thalambedu; Jaskirat Sehti; Samer Al Hadidi; Sharmilan Thanendrarajan; Monica Graziutti; Maurizio Zangari; Bart Barlogie; Frits van Rhee; Guido Tricot; Carolina Schinke
Journal:  J Clin Med       Date:  2022-03-16       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.